Technical Analysis for APRE - Aprea Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
NR7 | Range Contraction | -2.09% | |
NR7-2 | Range Contraction | -2.09% | |
Narrow Range Bar | Range Contraction | -2.09% | |
Inside Day | Range Contraction | -2.09% | |
Gapped Down | Weakness | -2.09% | |
NR7 | Range Contraction | -4.10% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 17 hours ago |
Down 2 % | about 17 hours ago |
Down 1% | about 17 hours ago |
Possible NR7 | about 17 hours ago |
Possible NR7 | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.8465 |
52 Week Low | 2.78 |
Average Volume | 36,443 |
200-Day Moving Average | 4.74 |
50-Day Moving Average | 6.50 |
20-Day Moving Average | 6.12 |
10-Day Moving Average | 5.94 |
Average True Range | 0.48 |
RSI (14) | 40.83 |
ADX | 21.49 |
+DI | 11.51 |
-DI | 23.39 |
Chandelier Exit (Long, 3 ATRs) | 5.43 |
Chandelier Exit (Short, 3 ATRs) | 6.77 |
Upper Bollinger Bands | 6.73 |
Lower Bollinger Band | 5.52 |
Percent B (%b) | 0.07 |
BandWidth | 19.66 |
MACD Line | -0.20 |
MACD Signal Line | -0.15 |
MACD Histogram | -0.0558 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.61 | ||||
Resistance 3 (R3) | 5.61 | 5.61 | 5.61 | ||
Resistance 2 (R2) | 5.61 | 5.61 | 5.61 | 5.61 | |
Resistance 1 (R1) | 5.61 | 5.61 | 5.61 | 5.61 | 5.61 |
Pivot Point | 5.61 | 5.61 | 5.61 | 5.61 | 5.61 |
Support 1 (S1) | 5.61 | 5.61 | 5.61 | 5.61 | 5.61 |
Support 2 (S2) | 5.61 | 5.61 | 5.61 | 5.61 | |
Support 3 (S3) | 5.61 | 5.61 | 5.61 | ||
Support 4 (S4) | 5.61 |